TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07465718: Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

Sponsor: Orphalan · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 38 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$2,074,336

Rescue Site Savings

+$1,367,176

Unlock Full NCT07465718 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07465718 Rescue Dossier →